GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes-Reference-Cited by-同舟云学术

GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes

Published:2024-08-01 Issue:2 Volume:327 Page:H370-H376
ISSN:0363-6135
Container-title:American Journal of Physiology-Heart and Circulatory Physiology
language:en
Short-container-title:American Journal of Physiology-Heart and Circulatory Physiology

Author:

Park Brady¹²³⁴^ORCID,Krishnaraj Aishwarya¹²³⁴^ORCID,Teoh Hwee¹²³⁵^ORCID,Bakbak Ehab¹²³⁴⁶^ORCID,Dennis Fallon¹²³⁴^ORCID,Quan Adrian¹²³^ORCID,Hess David A.²³⁴⁷⁸^ORCID,Verma Subodh¹²³⁴⁹^ORCID

Affiliation:

1. Division of Cardiac Surgery, St. Michael’s Hospital, Unity Health Toronto, Toronto, Ontario, Canada

2. Keenan Research Centre for Biomedical Science, St Michael’s Hospital, Toronto, Ontario, Canada

3. Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, Ontario, Canada

4. Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada

5. Division of Endocrinology and Metabolism, St. Michael’s Hospital, Unity Health Toronto, Toronto, Ontario, Canada

6. Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia

7. Department of Physiology and Pharmacology, Western University, London, Ontario, Canada

8. Molecular Medicine Research Laboratories, Robarts Research Institute, London, Ontario, Canada

9. Department of Surgery, University of Toronto, Toronto, Ontario, Canada

Abstract

In this post hoc subanalysis of 92 individuals living with T2D and at high cardiovascular risk, the authors summarize the differences in circulating vascular regenerative (VR) progenitor cell content between those on GLP-1RA therapy, on SGLT2 inhibitor without GLP-1RA therapy, and on neither therapy. Those on GLP-1RA therapy demonstrated greater circulating VR progenitor cell content and reduced proinflammatory granulocyte precursor content. These results offer novel mechanistic insights into the cardiometabolic benefits associated with GLP-1RA therapy.

Funder

Canadian Government | Canadian Institutes of Health Research

Heart and Stroke Foundation of Canada

Publisher

American Physiological Society

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpheart.00257.2024

Reference35 articles.

1. Global Burden of Cardiovascular Diseases and Risks, 1990-2022

2. Spending on Cardiovascular Disease and Cardiovascular Risk Factors in the United States: 1996 to 2016

3. The biology of incretin hormones

4. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

5. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vascular regeneration: a new mechanism of glucagon-like peptide-1 receptor agonist-mediated cardioprotection?;American Journal of Physiology-Heart and Circulatory Physiology;2024-08-01